From Cork to Maidenhead: An Irish nurse's story
A nurse who moved from Ireland to Berkshire in 1948 at the age of 19 to join the newly created National Health Service (NHS) was a "pioneer", her daughter has said.
Nora McCarthy was one of thousands of Irish women recruited to train and work in British hospitals after the end of World War Two.
Janie Davies said her mother, who died last year aged 95, "absolutely loved" her job as a nurse.
Speaking to Radio Berkshire ahead the 77th anniversary of the NHS on 5 July, she said her mother told her it had been "very strict" in the early days.
The NHS took control of 480,000 hospital beds in England and Wales in 1948 but it was short of 48,000 nurses so an active recruitment drive was launched in Ireland.
At the time, nurse training opportunities in Ireland were limited and expensive, making the chance to train for free in British hospitals with live-in accommodation highly attractive.
By the 1960s there were about 30,000 Irish nurses working in the NHS.
Ms Davies said her mother saw an advert and decided she wanted to help.
Nora first spent a year working at a hospital in Highgate, London, on an orthopaedic ward before an outbreak of tuberculosis (TB), she said.
"About summertime 1949, mum and her friend wanted to apply for a job in Maidenhead," she said.
"I think working a year on the TB ward was just getting to them, they were seeing a lot of death."
Nora spoke fondly of her time in the NHS, said Ms Davies, adding that during the early years she had said it was "very strict" but there was "a lot of camaraderie too".
She said her mother had told her of dances at the local church hall which the off-duty nurses would attend and where Nora met her future husband.
Ms Davies' daughter Ciara has retraced Nora's journey from Cork to working at Maidenhead General Hospital in Berkshire, as part of her university dissertation.
She said: "I started in Ireland, we went to the original green rooms in O'Donovan's where the [nursing] interviews had taken place.
"Then to where she caught the bus from in Cork. We saw a little bit of Maidenhead but the original building for Maidenhead General Hospital was no longer there.
"There were some surprises about her life that I didn't know, such as learning about tuberculosis and what her life was like on the TB ward."
Nora worked as an NHS nurse for 50 years, retiring at the age of 69.
Her story has been featured in a book, titled Irish Nurses in the NHS - An Oral History, which explores the life experiences of the Irish migrant nurses.
Its co-author Prof Louise Ryan said the NHS described how it was "actively recruiting" in Ireland, with advertisements in national and local papers.
NHS recruiters travelled throughout the country and carried out interviews with young women in local hotels.
Prof Ryan said: "Their travel was paid, they earned a salary while they trained - plus they got accommodation in the nurses home.
"If you can image parents waving their children off on this mammoth journey across the sea to England – knowing there was secure accommodation was very reassuring – they were very well looked after."
You can follow BBC Berkshire on Facebook, X (Twitter), or Instagram.
Nurses 'proud' to celebrate 40 years of NHS care
Nursery nurse congratulated for 45 years of service
NHS nurses and healthcare staff offered 5.5% pay rise
'NHS needs fewer managers, more nurses'
NHS
Irish Nurses in the NHS - An Oral History

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company's stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. A laboratory cultivating cells for the development of gene and cell therapies. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic islet cells that have been genetically modified using Sana's hypoimmune (HIP) technology to evade immune detection. A significant finding is that the transplanted cells were safe, well-tolerated, survived, and continued to produce insulin in the patient without the need for immunosuppressive medicines. The study identified no safety issues, and the HIP-modified islet cells successfully evaded immune responses (both allogeneic and autoimmune). Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician, and Professor at the Clinic for Uppsala University Hospital, stated that the consistent results at four-week, 12-week, and now six-month follow-ups continue to suggest that a functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. It develops engineered cell therapies to treat serious diseases, aiming to repair or replace damaged cells. Its platforms include hypoimmune cells, gene delivery, and in vivo cell engineering. Sana's pipeline targets conditions like cancer, type 1 diabetes, and genetic disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
an hour ago
- Yahoo
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
One major potential use case for AI in healthcare is drug discovery for pharmaceutical companies. Insurance is another healthcare-related industry likely to benefit from AI, which could aid scenario modeling, predictive analytics, and natural language processing. UnitedHealth Group experienced some operational challenges this year, but AI could wipe away these shortcomings in the long run. 10 stocks we like better than UnitedHealth Group › When it comes to popular healthcare stocks, investors have focused a lot of attention lately on Eli Lilly and Novo Nordisk and the potential of their blockbuster weight management treatments, including Mounjaro, Zepbound, Ozempic, and Wegovy. While these drugs are likely to lead to billions in revenue, Lilly and Novo aren't relying solely on these drugs to grow their businesses. Both companies are also looking into the potential that artificial intelligence (AI) can bring to their operations -- and for good reason. Accounting and consulting firm PwC estimates that the total addressable market (TAM) for AI in healthcare could reach $868 billion by 2030. One of the obvious applications that AI has for healthcare is facilitating pharmaceutical companies in clinical trials and drug discovery. While such use cases are exciting, I see another pocket of the healthcare industry that could be positively disrupted by AI: insurance. Let's explore why UnitedHealth Group (NYSE: UNH) could be an under-the-radar growth opportunity because of the intersection between healthcare and AI. Back in April, UnitedHealth greatly disappointed investors after the company published revised financial guidance that indicated a lower-than-expected earnings outlook for the remainder of the year. Management blamed the lower profitability on two primary factors. First, utilization rates in the company's Medicare Advantage program exceeded internal forecasts, taking a toll on the company's cost structure. Second, reimbursements in the company's pharmacy benefits management (PBM) platform, Optum Health, were negatively impacted by reductions in Medicare funding as well as changes to some of the patient demographic profiles in this segment of the business. In short order, the stock price plunged and has shown no indications of recovery, so far. For 2025, share prices are down 40%, making UnitedHealth the poorest-performing stock in the Dow Jones Industrial Average this year. But before you go writing UnitedHealth off as a broken business, let's examine how AI has the potential to help the health insurance industry and how UnitedHealth specifically could implement this technology to improve the business over time. The underlying issue surrounding UnitedHealth's challenges right now has to do with forecasting. There isn't anything fundamentally broken with the business. Rather, unforeseen changes in the macroeconomic environment led to a different reality than what management had previously modeled -- ultimately leading to higher costs and compressed profit margins. By using machine learning, UnitedHealth could train AI models on claims data and subsequently integrate these feeds into electronic health records (EHR) to help predict more accurate utilization trends. More efficient data feeds could help UnitedHealth hone its pricing strategy and better plan for cost spikes. In addition, AI has the ability to build predictive models that can more accurately assess patient risk profiles. In theory, this has the potential to analyze more granular detail around various segments of patient data as it relates to engagement rates and risk profiles. This could help improve reimbursement forecasts for the Optum business. Lastly, natural language processing (NLP) can also be used to create scenario models by simulating how a business could be impacted based on changes in the regulatory landscape. An example of a company that specializes in this area of AI training is FiscalNote. This could help UnitedHealth plan more strategically as it pertains to budgeting decisions during periods of political uncertainty. While shares of UnitedHealth trade at a slight premium to other large health insurers based on forward earnings multiples, the bigger takeaway from the trends below is that the stock price is hovering near a five-year low. While UnitedHealth's operational challenges won't be fixed overnight, it is key to remember that management believes the company can course correct throughout the second half of this year and be better positioned by 2026. Whether UnitedHealth transitions into an AI-powered service remains to be seen. Investors with a long-run time horizon might want to consider holding on to their shares, though, as the ideas explored above showcase how AI has the potential to become a game-changing advancement for the health insurance industry over time. Looked at a different way, UnitedHealth could transform its business over the next several years by making cognizant investments in this technology. Nevertheless, the stock appears dirt cheap right now, and I think patient investors will be rewarded as the company turns things around over the next couple of quarters. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Fiscal Note is a transcription service used by The Motley Fool. Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk and UnitedHealth Group. The Motley Fool has a disclosure policy. This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
2 hours ago
- Washington Post
I got an ambulance ride, CT scan and ER care in Brazil. My bill: $0.
PARATY, Brazil — My son had a high fever, so my wife and I decided to cut short our beach vacation and head home, worried about the quality of health care so far from Rio de Janeiro. I packed our bags, took one last look at the calm shoreline and headed out to load up the car.